Assuntos
Anemia Falciforme , Inibidores da Angiogênese/uso terapêutico , Ácido Butírico/uso terapêutico , Hemoglobina Fetal/biossíntese , Antagonistas dos Receptores Histamínicos/uso terapêutico , Talidomida/uso terapêutico , Talassemia beta , Anemia Falciforme/tratamento farmacológico , Anemia Falciforme/metabolismo , Inibidores da Angiogênese/agonistas , Animais , Ácido Butírico/agonistas , Sinergismo Farmacológico , Humanos , Talidomida/agonistas , Talassemia beta/tratamento farmacológico , Talassemia beta/metabolismoRESUMO
Recent data suggest that AT2 receptors in smooth muscle cells (VSMCs) of adult vessels may counterbalance AT1 receptor activity by inhibiting cell growth. The role of AT2 receptors in VSMC proliferation was investigated by using an in vitro organ culture model in which the sprouting of tubular structures was assessed. In preparations with endothelium, tubular growth was unaffected by angiotensin II (Ang II) but was inhibited by 50 +/- 9% by losartan and was increased by 110 +/- 15% by the AT2 antagonist PD123177. In endothelium-deprived preparations, growth inhibition (-49.1 +/- 0.5%) was observed when angiotensin II was added together with losartan 1 microM, whereas stimulation (59.8 +/- 14%) was induced by angiotensin II with 1 microM PD123177. In cultured VSMCs angiotensin II slightly promoted growth that was inhibited by losartan but was unaffected by PD123177. AT1a, AT1b, and AT2 mRNA expression was demonstrated in cells isolated from tubular structures grown from intact and endothelium-deprived rings, but only AT1a and AT1b mRNA was detected in cultured VSMCs. In conclusion, this paper proposes an in vitro organ culture model in which the expression of AT2 receptors in VSMCs is preserved and demonstrates AT2 receptor-mediated inhibition of VSMC proliferation in adult vessels.
